Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lucid-21-302 · 2 trials · 2 indications
Safety Outcome Measure
Safety Outcome Measure
Safety Outcome Measure
Safety blood test measured by a laboratory using a reference range
Safety blood test measured by a laboratory using a reference range
Safety blood test measured by a laboratory using a reference range
Safety urine test measured by a laboratory using a reference range
Safety Outcome Measure, clinical exam performed by a licensed physician
Safety Outcome Measure, measured in mmHg
Safety Outcome Measure, measured in mmHg
Safety Outcome Measure, measured in beats per minute
Safety Outcome Measure, measured in breaths per minute
Safety Outcome Measure, measured in degrees Celcius
Safety Outcome Measure, measured using a standard ECG machine
Safety Outcome Measure, PHQ-9 is a depression scale with scores ranging from 0 to 27 with higher scores indicating more depressive symptoms
Safety Outcome Measure, GAD7 is an anxiety scale with scores ranging from 0 to 21 with higher scores indicating more anxiety symptoms
Safety Outcome Measure, C-SSRS is an assessment tool that measures suicidal ideation and behavior. It consists of ten yes or no questions with yes answers indicating more thoughts of suicidality.
Safety Outcome Measure, neurological exam performed by a licensed physician
Incidence and severity of adverse events (AEs), laboratory, ECG, physical exam, neurological exam and vital sign changes
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
PK characteristics after single dose
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
Effect of food on the single dose PK
| Arm | Type | Description |
|---|---|---|
| Lucid-21-302 | EXPERIMENTAL | Multiple ascending dose cohorts |
| Placebo | PLACEBO_COMPARATOR | Multiple ascending dose cohorts |
| Name | Type | Description |
|---|---|---|
| Lucid-21-302 | DRUG | Capsule containing a small molecule inhibitor of hypercitrullination |
| Placebo | DRUG | Capsule containing only Silicified Microcrystalline Cellulose |
Inclusion Criteria: 1. Male or female, aged ≥18 and ≤60 years (inclusive), with BMI \>18.0 and \<32.0 kg/m2 and body weight ≥50.0 kg. Social smokers consuming less than 10 cigarettes per week, with a negative cotinine test at screening and Day -1 will be allowed. 2. Participant is judged by the Inv...
Lucid-21-302 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with trials evaluating its safety, tolerability, and pharmacokinetics. It has not been approved for any indication and remains under investigation.
Lucid-21-302 is being developed by Quantum Biopharma Ltd., a company listed on the stock exchange under the ticker QNTM. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
Lucid-21-302 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in Canada and one in Australia, both involving healthy adult participants. The drug is investigational and has not been approved by regulatory authorities.
Lucid-21-302 has two completed Phase 1 trials. NCT05821387 evaluated safety, tolerability, pharmacokinetics, and food effects in 40 healthy volunteers in Canada. NCT06595706 evaluated multiple ascending doses in 16 healthy participants in Australia. Both were randomized, double-blind, and placebo-controlled.
No alternative names for Lucid-21-302 have been reported. The drug is identified solely by its code name Lucid-21-302 in clinical trial registries and is being developed by Quantum Biopharma Ltd. under that designation.